TAFAMIDIS
Body System:
Manner of administration:Oral
Restriction
Indication: Transthyretin amyloid cardiomyopathy
Treatment phase: First PBS-subsidised prescription for this drug
Restriction
Indication: Transthyretin amyloid cardiomyopathy
Treatment phase: Second and subsequent PBS-subsidised prescriptions for this drug
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $10,022.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Vyndamax | |||||